At the news
? NEUTRALIMPACT 3/10 PRESS-RELEASE filed Jun 15, 2026 at 08:00 ET
OPKO Health presented preclinical data for OPK8801001, a long-acting hGH receptor antagonist for acromegaly, at ENDO 2026. In vitro data showed 20-fold greater potency than Pegvisomant, and in vivo data demonstrated dose-dependent IGF-1 suppression, suggesting potential for weekly dosing. However, these are early preclinical results with no clinical or regulatory milestones, limiting near-term impact.
- OPK8801001 is a novel long-acting hGH receptor antagonist for acromegaly.
- In vitro data showed approximately 20-fold greater potency than Pegvisomant.
- In vivo data demonstrated robust, dose-dependent, sustained suppression of IGF-1.
- Preclinical findings suggest potential for a once-weekly treatment alternative to daily therapies.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access